Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) saw a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 15,700 shares, a drop of 74.1% from the February 29th total of 60,600 shares. Based on an average daily trading volume, of 136,600 shares, the short-interest ratio is presently 0.1 days. Approximately 1.2% of the company’s stock are sold short.
Virax Biolabs Group Price Performance
Shares of VRAX stock opened at $0.71 on Thursday. Virax Biolabs Group has a 52 week low of $0.70 and a 52 week high of $8.54. The firm has a 50 day moving average of $0.88 and a two-hundred day moving average of $1.83.
Hedge Funds Weigh In On Virax Biolabs Group
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS Group AG purchased a new stake in shares of Virax Biolabs Group during the 3rd quarter worth $38,000. Virtu Financial LLC acquired a new stake in Virax Biolabs Group during the 4th quarter worth $35,000. Legal & General Group Plc acquired a new stake in Virax Biolabs Group during the 4th quarter worth $73,000. Finally, Armistice Capital LLC acquired a new stake in Virax Biolabs Group during the 4th quarter worth $178,000. Hedge funds and other institutional investors own 8.61% of the company’s stock.
About Virax Biolabs Group
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.
Featured Articles
- Five stocks we like better than Virax Biolabs Group
- How to Calculate Stock Profit
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- What is Short Interest? How to Use It
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- The Most Important Warren Buffett Stock for Investors: His Own
- Cintas or UniFirst: Investors Win Either Way
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.